Management of Lupus Nephritis: New Treatments and Updated Guidelines

Overview

Journal Kidney360

Specialty Nephrology

Date 2023 Aug 2

PMID 37528520

Authors

Rupali Avasare

Yelena Drexler

Dawn J Caster

Alla Mitrofanova

J Ashley Jefferson

Affiliations

Soon will be listed here.

Abstract

Management of lupus nephritis has evolved considerably over the past years. Here, we provide a comprehensive review of clinical trials that form the basis for the Kidney Disease: Improving Global Outcomes and EULAR/ERA-EDTA updated guidelines and present day trials that will change the landscape of lupus nephritis therapy in years to come. In addition, we highlight the issues related to cost of therapy, resistant disease, and downstream adverse effects of specific therapies.

Citing Articles

Ameliorative Effect of Combined Placenta-Derived Mesenchymal Stem Cells plus Platelet-rich Plasma on Polycystic Ovarian Model in Rats: A Biochemical and Histological Study.

Sarvestani M, Rajabzadeh A, Salimian M, Mazoochi T, Ghavipanjeh G Reprod Sci. 2025; 32(3):907-918.

PMID: 39856459 DOI: 10.1007/s43032-025-01791-0.

The Role of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Treating Lupus Nephritis: A Systematic Review.

Nagy S, Kesselman M Cureus. 2025; 16(12):e76130.

PMID: 39835073 PMC: 11745080. DOI: 10.7759/cureus.76130.

Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis.

Zhao X, Yang S, Li M, Wang Y Ren Fail. 2024; 46(2):2416605.

PMID: 39440406 PMC: 11500530. DOI: 10.1080/0886022X.2024.2416605.

Therapeutic JAK1 Inhibition Reverses Lupus Nephritis in a Mouse Model and Demonstrates Transcriptional Changes Consistent With Human Disease.

Twomey R, Perper S, Westmoreland S, Srinivasan S, Mathieu S, Frank K ACR Open Rheumatol. 2024; 6(12):900-911.

PMID: 39364807 PMC: 11638135. DOI: 10.1002/acr2.11745.

Anti-Smith Antibodies as a Predictive Factor for Developing Lupus Nephritis in Systemic Lupus Erythematosus Patients: A Systematic Review.

Saleem A, Zeeshan B, Dissanayake G, Zergaw M, Elgendy M, Billey A Cureus. 2024; 16(8):e66270.

PMID: 39238683 PMC: 11376143. DOI: 10.7759/cureus.66270.

References

Yap D, Thong K, Yung S, Tang C, Ma B, Chan T . Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. Lupus. 2019; 28(12):1460-1467. DOI: 10.1177/0961203319879990. View

Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

Houssiau F, Vasconcelos C, DCruz D, Sebastiani G, Garrido Ed E, Danieli M . Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46(8):2121-31. DOI: 10.1002/art.10461. View

Tse K, Tang C, Lam M, Yap D, Chan T . Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol. 2008; 36(1):76-81. DOI: 10.3899/jrheum.080517. View

Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z . Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2014; 162(1):18-26. DOI: 10.7326/M14-1030. View

Bruschi M, Sinico R, Moroni G, Pratesi F, Migliorini P, Galetti M . Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol. 2014; 25(11):2483-98. PMC: 4214525. DOI: 10.1681/ASN.2013090987. View

Jayne D, Rovin B, Mysler E, Furie R, Houssiau F, Trasieva T . Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022; 81(4):496-506. PMC: 8921596. DOI: 10.1136/annrheumdis-2021-221478. View

Rathi M, Goyal A, Jaryal A, Sharma A, Gupta P, Ramachandran R . Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2015; 89(1):235-42. DOI: 10.1038/ki.2015.318. View

Thanei S, Vanhecke D, Trendelenburg M . Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways. Clin Immunol. 2015; 160(2):180-7. DOI: 10.1016/j.clim.2015.06.014. View

10.

Panda A, Parida J, Tripathy R, Pattanaik S, Ravindran B, Das B . Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity. Arthritis Res Ther. 2012; 14(5):R218. PMC: 3580530. DOI: 10.1186/ar4057. View

11.

Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

12.

Palazzo L, Lindblom J, Mohan C, Parodis I . Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature. J Clin Med. 2022; 11(19). PMC: 9570701. DOI: 10.3390/jcm11195759. View

13.

Baker K, Edwards B, Main S, Choi G, Wager R, Halpern W . Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003; 48(11):3253-65. DOI: 10.1002/art.11299. View

14.

Stahn C, Buttgereit F . Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008; 4(10):525-33. DOI: 10.1038/ncprheum0898. View

15.

Furie R, Aroca G, Cascino M, Garg J, Rovin B, Alvarez A . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021; 81(1):100-107. PMC: 8762029. DOI: 10.1136/annrheumdis-2021-220920. View

16.

Hanly J, OKeeffe A, Su L, Urowitz M, Romero-Diaz J, Gordon C . The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2015; 55(2):252-62. PMC: 4939728. DOI: 10.1093/rheumatology/kev311. View

17.

Rovin B, Teng Y, Ginzler E, Arriens C, Caster D, Romero-Diaz J . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10289):2070-2080. DOI: 10.1016/S0140-6736(21)00578-X. View

18.

Ghiggeri G, DAlessandro M, Bartolomeo D, DeglInnocenti M, Magnasco A, Lugani F . An Update on Antibodies to Necleosome Components as Biomarkers of Sistemic Lupus Erythematosus and of Lupus Flares. Int J Mol Sci. 2019; 20(22). PMC: 6888059. DOI: 10.3390/ijms20225799. View

19.

Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M . Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022; 28(10):2124-2132. DOI: 10.1038/s41591-022-02017-5. View

20.

Furie R, Rovin B, Houssiau F, Malvar A, Teng Y, Contreras G . Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020; 383(12):1117-1128. DOI: 10.1056/NEJMoa2001180. View